BioVaxys Technology Cash Flow Statement

Financials in millions CAD. Fiscal year is November - October.

Millions CAD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jul '25 Jul 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021	Oct '20 Oct 31, 2020
Net Income	-5.99	-3.95	-7.69	-11.73	-6.46	-1.17
Asset Writedown & Restructuring Costs	1.29	1.29	1.45	7.4	-	-
Stock-Based Compensation	0.33	0.3	3.25	0.62	1.25	0.35
Other Operating Activities	-0.65	0.45	-0.25	0.23	-0	0.07
Change in Accounts Payable	1.68	0.69	1.8	1.98	-0.5	0.18
Change in Other Net Operating Assets	0.38	-0.64	0.39	-0.07	0.42	-0.63
Operating Cash Flow	-2.97	-1.86	-1.05	-1.57	-5.29	-1.23
Cash Acquisitions	-	-	-	-	-	0.04
Sale (Purchase) of Intangibles	-	-1.06	-	-	-	-
Other Investing Activities	-	-	-	-	-	0.02
Investing Cash Flow	-	-1.06	-	-	-	0.06
Short-Term Debt Repaid	-	-0.03	-	-	-	-
Total Debt Repaid	-0.03	-0.03	-	-	-	-
Net Debt Issued (Repaid)	-0.05	-0.03	-	-	-	-
Issuance of Common Stock	2.53	3.16	0.92	1.13	3.78	3.33
Other Financing Activities	-	-	-	-0.03	-0.34	0.02
Financing Cash Flow	2.48	3.13	0.92	1.11	3.44	3.35
Foreign Exchange Rate Adjustments	0	0	-0	0.02	0.03	0.01
Net Cash Flow	-0.49	0.21	-0.14	-0.45	-1.83	2.19
Levered Free Cash Flow	-1.03	-4.01	4.06	-0.74	-2.71	-0.06
Unlevered Free Cash Flow	-1.03	-4.01	4.06	-0.74	-2.71	-0.06
Change in Working Capital	2.06	0.05	2.19	1.9	-0.08	-0.45

Updated Jul 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.